Transgene (TRGNF) Stock Price, News & Analysis

Company Overview

Transgene is a France-based biotechnology company focused on developing immunotherapies for the treatment of cancer. The company specializes in therapeutic vaccines and other biological treatments designed to stimulate or direct the immune system against tumor cells, using technologies that include viral vectors.

Its pipeline has included TG4050, an individualized cancer vaccine developed with NEC that is designed to target patient-specific tumor mutations. Transgene has also developed TG4001, an investigational therapeutic vaccine targeting human papillomavirus-related cancers, along with other viral-vector programs such as TG6002. These candidates remain subject to clinical development and regulatory evaluation, and the company does not represent all of them as approved commercial products.

Founded in 1979, Transgene is headquartered in Strasbourg, France, and operates within the Institut Mérieux group. Its research and development activities are conducted through collaborations and clinical programs involving partners and institutions in Europe and other international markets. The company is listed on Euronext Paris and also trades in the United States over the counter under the symbol TRGNF.

Key Stats

• Today's Range: $0.80 to $0.80
• 50-Day Range: $0.80 to $0.85
• 52-Week Range: $0.80 to $0.85
• Volume: N/A
• Average Volume: 433 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:TRGNF
• CIK: N/A
• Web: www.transgene.fr
• Phone: (338) 827-9100
• Fax: N/A
• Employees: 146
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A